Effect of sulodexide on plasma transforming growth factor-β1 in healthy volunteers

Clinical and Applied Thrombosis/Hemostasis

Volumn 16, Issue 1, 2010, Pages 60-65

  Borawski, Jacek ^a   Dubowski, Miroslaw ^a   Pawlak, Krystyna ^a   Mysliwiec, Michal ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Glycosaminoglycan; Humans; Sulodexide; Transforming growth factor 1

Indexed keywords

CYTOKINE; SULODEXIDE; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; CYTOKINE RELEASE; DOWN REGULATION; DRUG EFFECT; GENE EXPRESSION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PILOT STUDY; PRIORITY JOURNAL; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; DOWN-REGULATION; FIBRINOLYTIC AGENTS; GLYCOSAMINOGLYCANS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 76049101885     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029608326170     Document Type: Article

References (29)

1. Harenberg J. Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev. 1998 ; 18: 1-20.
2. Ofosu FA Pharmacological actions of sulodexide. Semin Thromb Hemost. 1998 ; 24: 127-138.
3. Abaterusso C., Gambaro G. The role of glycosaminoglycans and sulodexide in the treatment of diabetic nephropathy. Treat Endocrinol. 2006 ; 5: 211-222.
4. Wijnhoven TJ, Lensen JF, Rops AL, et al. Anti-proteinuric effects of glycosaminoglycan-based drugs. Curr Opin Mol Ther. 2007 ; 9: 364-377.
5. Lauver DA, Lucchesi BR Sulodexide: a renewed interest in this glycosaminoglycan. Cardiovasc Drug Rev. 2006 ; 24: 214-226.
6. Gozdzikiewicz J., Borawski J., Mysliwiec M. Pleiotropic effects of heparin and heparinoids in peritoneal dialysis. Clin Appl Thromb Hemost. 2007. doi. 10.1177/ 1076029607304722..
7. Borawski J., Zbroch E., Rydzewska-Rosolowska A., Pawlak K., Mysliwiec M. Sulodexide for hemodialysis anticoagulation in heparin-induced thrombocytopenia type II. J Nephrol. 2007 ; 20: 370-372.
8. Elsayed E., Becker RC The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development. J Thromb Thrombolysis. 2003 ; 15: 11-18.
9. Munoz EM, Linhard RJ Heparin-binding domains in vascular biology. Arterioscler Thromb Vasc Biol. 2004 ; 24: 1549-1557.
10. Norrby K. Low-molecular-weight heparins and angiogenesis. APMIS. 2006 ; 114: 79-102.
11. Blobe GC, Schiemann WP, Lodish HF Role of transforming growth factor beta in human disease. N Engl J Med. 2000 ; 342: 1350-1358.
12. Böttinger EP TGF-beta in renal injury and disease. Semin Nephrol. 2007 ; 27: 309-320.
13. Redondo S., Santos-Gallego CG, Tejerina T. TGF-beta 1: a novel target for cardiovascular pharmacology. Cytokine Growth Factor Rev. 2007 ; 18: 279-286.
14. Prudghomme GJ Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest. 2007 ; 87: 1077-1091.
15. Wahl SM Transforming growth factor beta: innately bipolar. Curr Opin Immunol. 2007 ; 19: 55-62.
16. Taipale J., Keski-Oja J. Growth factors in the extracellular matrix. FASEB J. 1997 ; 11: 51-59.
17. Taylor KR, Gallo RL Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J. 2006 ; 20: 9-22.
18. Rider CC Heparin/heparan sulphate binding in the TGF-beta cytokine superfamily. Biochem Soc Trans. 2006 ; 34: 458-460.
19. Chen Q., Sivakumar P., Barley C., et al. Potential role for heparan sulfate proteoglycans in regulation of TGF-beta by modulating assembly of latent TGF-beta binding protein-1 (LTBP-1). J Biol Chem. 2007 ; 282: 26418-26430.
20. Grainger DJ, Mosedale DE, Metcalfe JC (2000) TGF-beta in blood: a complex problem. Cytokine Growth Factor Rev. 2000; 11: 133-145.
21. Annes JP, Munger JS, Rifkin DB Making sense of latent TGF-beta activation. J Cell Sci. 2003 ; 116: 217-224.
22. Ceol M., Gambaro G., Sauer U., et al. Glycosaminoglycan therapy prevents TGF-beta1 overexpression and pathologic changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol. 2000 ; 11: 2324-2336.
23. Weigert C., Brodbeck K., Haring HU, Gambaro G., Schleicher ED Low-molecular-weight heparin prevents high glucose- and phorbol ester-induced TGF-beta 1 gene activation. Kidney Int. 2001 ; 60: 935-943.
24. Ceol M., Vianello D., Schleicher E., et al. Heparin reduces glomerular infiltration and TGF-beta protein expression by macrophages in puromycin glomerulosclerosis. J Nephrol. 2003 ; 16: 210-218.
25. Pecly IM, Goncalves RG, Rangel EP, et al. Effects of low molecular weight heparin in obstructed kidneys: decrease of collagen, fibronectin and TGF-beta, and increase of chondroitin/dermatan sulfate proteoglycans and macrophage infiltration. Nephrol Dial Transplant. 2006 ; 21: 1212-1222.
26. Naumnik B., Borawski J., Pawlak K., Mysliwiec M. Enoxaparin but not unfractionated heparin causes a dose-dependent increase in circulating TGF-beta1 during haemodialysis: a cross-over study. Nephrol Dial Transplant. 2007 ; 22: 1690-1696.
27. McCaffrey TA, Falcone DJ, Brayton CF, Agarwal LA, Welt FG, Weksler BB Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2-macroglobulin inactive complex. J Cell Biol. 1989 ; 109: 441-448.
28. Tardieu M., Bourin MC, Desgranges P., Barbier P., Barritault D., Caruelle JP Mesoglycan and sulodexide act as stabilizers and protectors of fibroblast growth factors (FGFs). Growth Factors. 1994 ; 11: 291-300.
29. Borawski J., Dubowski M., Pawlak K., Mysliwiec M. Sulodexide induces hepatocyte growth factor release in humans. Eur J Pharmacol. 2007 ; 558: 167-171.